⭐️⭐️⭐️⭐️⭐️ "A total no brainer"

⭐️⭐️⭐️⭐️⭐️ "Love this, so easy."

Spots is the easy way to track your skin, mole and cancer changes.

Spots Global Cancer Trial Database for oesophageal squamous cell carcinoma

Every month we try and update this database with for oesophageal squamous cell carcinoma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study titleNCT IDConditionsInterventionsEligibilityOrganizationLink
A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With Gastrointestinal Cancer (Master Protocol) (Pegathor Gastrointestinal 203)NCT05104567
Oesophageal Squ...
Gastric Cancer
Hepatocellular ...
Colorectal Canc...
Oesophageal Ade...
THOR-707
Pembrolizumab
Cetuximab
18 Years - Sanofi
Study of Intratumorally Administered Stimulator of Interferon Genes (STING) Agonist E7766 in Participants With Advanced Solid Tumors or Lymphomas - INSTAL-101NCT04144140
Lymphoma
Advanced Solid ...
E7766
18 Years - Eisai Inc.
Study of Intratumorally Administered Stimulator of Interferon Genes (STING) Agonist E7766 in Participants With Advanced Solid Tumors or Lymphomas - INSTAL-101NCT04144140
Lymphoma
Advanced Solid ...
E7766
18 Years - Eisai Inc.
A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With Gastrointestinal Cancer (Master Protocol) (Pegathor Gastrointestinal 203)NCT05104567
Oesophageal Squ...
Gastric Cancer
Hepatocellular ...
Colorectal Canc...
Oesophageal Ade...
THOR-707
Pembrolizumab
Cetuximab
18 Years - Sanofi
NeoAdjuvant Therapy With Immunoreagent (SHR-1316) for Resectable Oesophageal Squamous Cell carciNomaNCT04215471
Oesophageal Squ...
PD-L1 Antibody ...
18 Years - 75 YearsShanghai Zhongshan Hospital
A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With Gastrointestinal Cancer (Master Protocol) (Pegathor Gastrointestinal 203)NCT05104567
Oesophageal Squ...
Gastric Cancer
Hepatocellular ...
Colorectal Canc...
Oesophageal Ade...
THOR-707
Pembrolizumab
Cetuximab
18 Years - Sanofi
Study of Anti-PD-L1 in Combination With Chemo(Radio)Therapy for Oesophageal CancerNCT02735239
Esophageal Canc...
Durvalumab
Tremelimumab
Oxaliplatin
Capecitabine
Radiotherapy
Paclitaxel
Carboplatin
5-fluorouracil ...
Leucovorin
Docetaxel
18 Years - Ludwig Institute for Cancer Research
Logo

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

spots app storespots app store

Join others from around the world: